Platelet-derived growth factor-induced severe and chronic vasoconstriction of cerebral arteries: Proposed growth factor explanation of cerebral vasospasm

Zhi Wen Zhang, Hiroji Yanamoto, Izumi Nagata, Susumu Miyamoto, Yukako Nakajo, Jing Hui Xue, Koji Iihara, Haruhiko Kikuchi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

OBJECTIVE: After subarachnoid hemorrhage (SAH), platelet-derived growth factor-BB (PDGF-BB) is secreted in and around the cerebral arteries. To clarify the role of PDGF-BB in the development of vasospasm after SAH, we determined whether PDGF-BB alone can cause long-lasting vasoconstriction of a severity similar to that of vasospasm. In addition, the anti-vasospastic effect of trapidil, an antagonist of PDGF-BB function, was investigated. METHODS: We infused recombinant PDGF-BB (10 μg/mL saline as the vehicle) (n = 14) into the subarachnoid space of rabbits and analyzed alterations in the caliber of the basilar artery using repeated angiography. To study the role of PDGF-BB on the development of vasospasm, trapidil was administered continuously starting 1 hour after SAH, on day 0 (0.63-1.25 mg/kg /h or vehicle) for 47 hours (n = 24), or after the full development of cerebral vasospasm on day 2 (3.0 mg/kg/h or vehicle) for 0.5 hours (n = 17), and alterations in the caliber of the basilar artery were monitored. RESULTS: PDGF-BB caused long-lasting vasoconstriction, with maximum constriction of 56% (P < .001) of the control value (= 100%) on day 2, resembling vasospasm seen after SAH. Prolonged administration of intravenous trapidil, starting soon after SAH, prevented the development of vasospasm in a dose-dependent manner (P < .05, .01, or .001). Intravenous or intra-arterial administration of trapidil significantly dilated vasospasm (P < .01) on day 2, at least transiently. CONCLUSION: PDGF-BB, a growth factor synthesized in the subarachnoid space after SAH, can cause severe and long-lasting vasoconstriction. Significant prevention and resolution of vasospasm can be achieved by the PDGF-BB antagonist trapidil. We propose that excessive production of PDGF-BB, essentially aiming to repair injured arteries, causes cerebral vasospasm. Although the half-life of trapidil in serum may be shorter than that of PDGFG-BB-derived spasmogenic signaling, trapidil is a candidate drug for constructing a new therapeutic modality for preventing and resolving vasospasm.

Original languageEnglish
Pages (from-to)728-735
Number of pages8
JournalNeurosurgery
Volume66
Issue number4
DOIs
Publication statusPublished - Apr 1 2010

Fingerprint

Intracranial Vasospasm
Cerebral Arteries
Trapidil
Platelet-Derived Growth Factor
Vasoconstriction
Intercellular Signaling Peptides and Proteins
Subarachnoid Hemorrhage
Subarachnoid Space
Basilar Artery
platelet-derived growth factor BB
Constriction
Intravenous Administration
Half-Life
Angiography
Arteries
Rabbits

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Cite this

Platelet-derived growth factor-induced severe and chronic vasoconstriction of cerebral arteries : Proposed growth factor explanation of cerebral vasospasm. / Zhang, Zhi Wen; Yanamoto, Hiroji; Nagata, Izumi; Miyamoto, Susumu; Nakajo, Yukako; Xue, Jing Hui; Iihara, Koji; Kikuchi, Haruhiko.

In: Neurosurgery, Vol. 66, No. 4, 01.04.2010, p. 728-735.

Research output: Contribution to journalArticle

Zhang, Zhi Wen ; Yanamoto, Hiroji ; Nagata, Izumi ; Miyamoto, Susumu ; Nakajo, Yukako ; Xue, Jing Hui ; Iihara, Koji ; Kikuchi, Haruhiko. / Platelet-derived growth factor-induced severe and chronic vasoconstriction of cerebral arteries : Proposed growth factor explanation of cerebral vasospasm. In: Neurosurgery. 2010 ; Vol. 66, No. 4. pp. 728-735.
@article{f09a59696f7441c7abc80e5d41c49f13,
title = "Platelet-derived growth factor-induced severe and chronic vasoconstriction of cerebral arteries: Proposed growth factor explanation of cerebral vasospasm",
abstract = "OBJECTIVE: After subarachnoid hemorrhage (SAH), platelet-derived growth factor-BB (PDGF-BB) is secreted in and around the cerebral arteries. To clarify the role of PDGF-BB in the development of vasospasm after SAH, we determined whether PDGF-BB alone can cause long-lasting vasoconstriction of a severity similar to that of vasospasm. In addition, the anti-vasospastic effect of trapidil, an antagonist of PDGF-BB function, was investigated. METHODS: We infused recombinant PDGF-BB (10 μg/mL saline as the vehicle) (n = 14) into the subarachnoid space of rabbits and analyzed alterations in the caliber of the basilar artery using repeated angiography. To study the role of PDGF-BB on the development of vasospasm, trapidil was administered continuously starting 1 hour after SAH, on day 0 (0.63-1.25 mg/kg /h or vehicle) for 47 hours (n = 24), or after the full development of cerebral vasospasm on day 2 (3.0 mg/kg/h or vehicle) for 0.5 hours (n = 17), and alterations in the caliber of the basilar artery were monitored. RESULTS: PDGF-BB caused long-lasting vasoconstriction, with maximum constriction of 56{\%} (P < .001) of the control value (= 100{\%}) on day 2, resembling vasospasm seen after SAH. Prolonged administration of intravenous trapidil, starting soon after SAH, prevented the development of vasospasm in a dose-dependent manner (P < .05, .01, or .001). Intravenous or intra-arterial administration of trapidil significantly dilated vasospasm (P < .01) on day 2, at least transiently. CONCLUSION: PDGF-BB, a growth factor synthesized in the subarachnoid space after SAH, can cause severe and long-lasting vasoconstriction. Significant prevention and resolution of vasospasm can be achieved by the PDGF-BB antagonist trapidil. We propose that excessive production of PDGF-BB, essentially aiming to repair injured arteries, causes cerebral vasospasm. Although the half-life of trapidil in serum may be shorter than that of PDGFG-BB-derived spasmogenic signaling, trapidil is a candidate drug for constructing a new therapeutic modality for preventing and resolving vasospasm.",
author = "Zhang, {Zhi Wen} and Hiroji Yanamoto and Izumi Nagata and Susumu Miyamoto and Yukako Nakajo and Xue, {Jing Hui} and Koji Iihara and Haruhiko Kikuchi",
year = "2010",
month = "4",
day = "1",
doi = "10.1227/01.NEU.0000366111.08024.26",
language = "English",
volume = "66",
pages = "728--735",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Platelet-derived growth factor-induced severe and chronic vasoconstriction of cerebral arteries

T2 - Proposed growth factor explanation of cerebral vasospasm

AU - Zhang, Zhi Wen

AU - Yanamoto, Hiroji

AU - Nagata, Izumi

AU - Miyamoto, Susumu

AU - Nakajo, Yukako

AU - Xue, Jing Hui

AU - Iihara, Koji

AU - Kikuchi, Haruhiko

PY - 2010/4/1

Y1 - 2010/4/1

N2 - OBJECTIVE: After subarachnoid hemorrhage (SAH), platelet-derived growth factor-BB (PDGF-BB) is secreted in and around the cerebral arteries. To clarify the role of PDGF-BB in the development of vasospasm after SAH, we determined whether PDGF-BB alone can cause long-lasting vasoconstriction of a severity similar to that of vasospasm. In addition, the anti-vasospastic effect of trapidil, an antagonist of PDGF-BB function, was investigated. METHODS: We infused recombinant PDGF-BB (10 μg/mL saline as the vehicle) (n = 14) into the subarachnoid space of rabbits and analyzed alterations in the caliber of the basilar artery using repeated angiography. To study the role of PDGF-BB on the development of vasospasm, trapidil was administered continuously starting 1 hour after SAH, on day 0 (0.63-1.25 mg/kg /h or vehicle) for 47 hours (n = 24), or after the full development of cerebral vasospasm on day 2 (3.0 mg/kg/h or vehicle) for 0.5 hours (n = 17), and alterations in the caliber of the basilar artery were monitored. RESULTS: PDGF-BB caused long-lasting vasoconstriction, with maximum constriction of 56% (P < .001) of the control value (= 100%) on day 2, resembling vasospasm seen after SAH. Prolonged administration of intravenous trapidil, starting soon after SAH, prevented the development of vasospasm in a dose-dependent manner (P < .05, .01, or .001). Intravenous or intra-arterial administration of trapidil significantly dilated vasospasm (P < .01) on day 2, at least transiently. CONCLUSION: PDGF-BB, a growth factor synthesized in the subarachnoid space after SAH, can cause severe and long-lasting vasoconstriction. Significant prevention and resolution of vasospasm can be achieved by the PDGF-BB antagonist trapidil. We propose that excessive production of PDGF-BB, essentially aiming to repair injured arteries, causes cerebral vasospasm. Although the half-life of trapidil in serum may be shorter than that of PDGFG-BB-derived spasmogenic signaling, trapidil is a candidate drug for constructing a new therapeutic modality for preventing and resolving vasospasm.

AB - OBJECTIVE: After subarachnoid hemorrhage (SAH), platelet-derived growth factor-BB (PDGF-BB) is secreted in and around the cerebral arteries. To clarify the role of PDGF-BB in the development of vasospasm after SAH, we determined whether PDGF-BB alone can cause long-lasting vasoconstriction of a severity similar to that of vasospasm. In addition, the anti-vasospastic effect of trapidil, an antagonist of PDGF-BB function, was investigated. METHODS: We infused recombinant PDGF-BB (10 μg/mL saline as the vehicle) (n = 14) into the subarachnoid space of rabbits and analyzed alterations in the caliber of the basilar artery using repeated angiography. To study the role of PDGF-BB on the development of vasospasm, trapidil was administered continuously starting 1 hour after SAH, on day 0 (0.63-1.25 mg/kg /h or vehicle) for 47 hours (n = 24), or after the full development of cerebral vasospasm on day 2 (3.0 mg/kg/h or vehicle) for 0.5 hours (n = 17), and alterations in the caliber of the basilar artery were monitored. RESULTS: PDGF-BB caused long-lasting vasoconstriction, with maximum constriction of 56% (P < .001) of the control value (= 100%) on day 2, resembling vasospasm seen after SAH. Prolonged administration of intravenous trapidil, starting soon after SAH, prevented the development of vasospasm in a dose-dependent manner (P < .05, .01, or .001). Intravenous or intra-arterial administration of trapidil significantly dilated vasospasm (P < .01) on day 2, at least transiently. CONCLUSION: PDGF-BB, a growth factor synthesized in the subarachnoid space after SAH, can cause severe and long-lasting vasoconstriction. Significant prevention and resolution of vasospasm can be achieved by the PDGF-BB antagonist trapidil. We propose that excessive production of PDGF-BB, essentially aiming to repair injured arteries, causes cerebral vasospasm. Although the half-life of trapidil in serum may be shorter than that of PDGFG-BB-derived spasmogenic signaling, trapidil is a candidate drug for constructing a new therapeutic modality for preventing and resolving vasospasm.

UR - http://www.scopus.com/inward/record.url?scp=77949976466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949976466&partnerID=8YFLogxK

U2 - 10.1227/01.NEU.0000366111.08024.26

DO - 10.1227/01.NEU.0000366111.08024.26

M3 - Article

C2 - 20305494

AN - SCOPUS:77949976466

VL - 66

SP - 728

EP - 735

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 4

ER -